bf/NASDAQ:AGLE_icon.jpeg

NASDAQ:AGLE

Aeglea BioTherapeutics, Inc.

  • Stock

USD

Last Close

11.26

27/11 21:00

Market Cap

48.63M

Beta: 1.76

Volume Today

43.24K

Avg: 725.60K

PE Ratio

−0.18

PFCF: −0.56

OverviewFinancialsAPI

    Description

    Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 de...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -40-30-20-102014-12-312017-03-232019-03-072021-03-182023-03-02

    Revenue (Estimate*)

    5M10M2014-12-312017-03-232019-03-072021-03-182023-03-02

    *Estimate based on analyst consensus